Hepatitis C virus and the disease that it produces;El virus C de la hepatitis y las enfermedades que produce

Revista Medica de Chile

Volumn 127, Issue 10, 1999, Pages 1240-1254

  Armas Merino, Rodolfo ^a   Wolff F, Carlos ^a   Soto H, Ramón ^a   Jirón V, M Isabel ^a   Parraguez A, Adriana ^a  

^a HOSPITAL SAN JUAN DE DIOS   (Chile)

Author keywords

Hepatitis C Viruses; Hepatitis, Chronic Active; Interferons; Liver Transplantation

Indexed keywords

ANTIVIRUS AGENT;

ACUTE DISEASE; CHILE; CRYOGLOBULINEMIA; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PORPHYRIA CUTANEA TARDA; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; VIROLOGY;

ACUTE DISEASE; ANTIVIRAL AGENTS; CHILE; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; PORPHYRIA CUTANEA TARDA; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 0033206260     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. HOUGHTON M, WEINER AJ, HAN J, KUO G, CHOO QL. Molecular biology of the hepatitis C virus: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 391-8.
2. CHOO QL, KUO G, WEINER AJ, OWERBEY LR, BRADLY DW, HOUGHTON M. Isolation of cDNA clone derived from a blood borne NoA, NoB viral hepatitis genome. Science 1989; 244: 359-62.
3. HERRERO C, VICENTE A, BRUGUERA M, ERCILLA MG, BARRERA JM, VIDAL J ET AL. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 788-9.
4. DE CASTRO M, SÁNCHEZ J, HERRERA JF, CHAVES A, DURÁN R, GARCÍA-BUEY L ET AL. Hepatitis C virus antibodies and liver diseases in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-7.
5. FARGION S, PIPERNO A, CAPPELLINI MD, SAMPIETRO M, FRACANZANI AL, ROMANO R ET AL. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322-6.
6. LACOUR JP, BODOKH I, CASTANET J, BEKRI S, ORTONNE JP. Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 1993; 23: 851-5.
7. FERRI C, BAICCHI U, LA CIVITA L, GRECO F, LONGOMBARDO G, MAZZONI A ET AL. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 1993; 23: 851-5.
8. WOLFF C, MUÑOZ G, ARMAS MERINO R, VELASCO M, PARRAGUEZ A, GUGLIELMETTI A. Genotipo del virus C de la hepatitis en pacientes con porfiria cutánea tarda. Rev Arg Dermatol 1997; 78: 158-61.
9. KOFF RS, DIENSTAG JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15: 101-9.
10. BEFRITS R, HEDMAN M, BLOMQUIST L, ALLANDER T, GRILLNER L, KINNMAN N ET AL. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995; 30: 1113-8.
11. COELHO-LITTLE ME, JEFFERS LJ, BERNSTEIN DE, GOODMAN JJ, REDDY KR, DE MEDINA M ET AL. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995; 19: 1173-6.
12. NODA K, YOSHIHARA H, SUZUKI K, YAMADA Y, KASAHARA A, HAYASHI N ET AL. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996; 2: 95A-100A.
13. OHNISHI K, MATSUO S, MATSUTANI K, ITAHASHI M, KAKIHARA K, SUZUKI K. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-9.
14. OKAZAKI T, YOSHIHARA H, SUZUKI K, YAMADA Y, TSUJIMURA T, KAWANO K ET AL. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039-43.
15. ARMAS MERINO R, SOTO JR. El espectro creciente de las hepatitis virales. Bol Hosp S J de Dios 1994; 41: 308-18.
16. MUÑOZ G, VELASCO M, THIERS V, HURTADO C, BRAHM J, LARRONDO-LILLO M ET AL. Prevalencia y genotipos del virus de la hepatitis C en donantes de sangre y en pacientes con enfermedad hepática crónica y hepatocarcinoma en población chilena. Rev Méd Chile 1998; 126: 1035-42.
17. ALTER MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-5S.
18. DI BISCEGLIE AM. Hepatitis C. Lancet 1998; 35: 351-6.
19. WOLFF C, JIRÓN MI, ELGUETA R, VERA M, TORIELLO L, MARTÍNEZ L ET AL. Prevalencia de anticuerpos anti virus C de la hepatitis en dadores de sangre. Análisis de resultados confirmados. Rev Méd Chile 1996; 124: 615-6.
20. ALEGRÍA S, MORALES M, VILDÓSOLA J, HURTADO C, BRAHM J. Infección con los virus de la hepatitis B y C en niños con trastornos congénitos de la coagulación. Rev Méd Chile 1994; 122: 638-42.
21. BRAHM J. Virus de la hepatitis C en hemodializados y trasplantados renales. (Editorial) Rev Méd Chile 1993; 121: 1043.
22. CASTILLO L, DÍAZ P, INOSTROZA J, ESPINOZA R, MILLAQUEO L, CALDERARA M ET AL. Prevalencia de anticuerpos del virus de la hepatitis C en hemodializados crónicos y trasplantados renales. Rev Méd Chile 1993; 121: 1024-8.
23. IBARRA H, MEZZANO S, RIEDEMANN S, TOLEDO C, ARDILES L, REINHARDT G, CASTILLO A. Virus de hepatitis C y trasplante renal. (Carta al Editor). Rev Méd Chile 1992; 120: 81-2.
24. RODRÍGUEZ MI, ESTAY R, SOTO JR, WOLFF C, PLUBINS L, CHILD R, ARMAS R. Prevalencia de anticuerpos contra el virus de la hepatitis C en una unidad de hemodiálisis. Rev Méd Chile 1993; 121: 152-5.
25. IBARRA H, RIEDEMANN S, MEZZANO S, TOLEDO C, REINHARDT G, NÚÑEZ M ET AL. Virus Hepatitis C: Resultados de detección en algunos grupos de riesgo en la X Región de Chile. Rev Méd Chile 1995; 123: 439-44.
26. VELASCO M, HURTADO C, BRAHM J. Anticuerpos anti-virus hepatititis C (VHC) en diversos cuadros patológicos en Chile. Rev Méd Chile 1990; 118: 895-6.
27. National Institutes of Health Consensus development conference panel statement: Management of hepatitis C. Hepatology 1997; 26 (Suppl, 1): 2S-10S.
28. TANAKA E, ALTER HJ, NAKATSUJI Y, SHIH JW, KIM JP, MATSUMOTO A ET AL. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996; 125: 740-3.
29. MARTINOT M, MARCELLIN P, BOYER N, DETMER J, POUTEAU M, CASTELNAU C ET AL. Influence of hepatitis G virus infection on the severity of liver disease and response to Interferon-α in patients with chronic hepatitis C. Ann Intern Med 1997; 126: 874-81.
30. BERENGUER M, TERRAULT NA, PIATAK M, YUN A, KIM JP, LAU JYN ET AL. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 1996; 111: 1569-75.
31. OSTAPOWICS G, WATSON KJR, LOCARNINI SA, DESMMOND PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-5.
32. FARINATI F, CARDAN R, DE MARÍA N, DELLA LIBERA G, MARAFIN C, LECIS E ET AL. Iron storage, lipid peroxidation and glutathion turnover in chronic anti-VHC positive hepatitis. J Hepatol 1995; 22: 449-56.
33. IMAI Y, KAWATA S, TAMURA S, YABUUCHI I, NODA S, INADA M ET AL. Relation of Interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-9.
34. SILVA H, MUÑOZ G, SÁNCHEZ G, JIRÓN MI, WOLFF C, VARAS A ET AL. Anticuerpos anti-virus C de la hepatitis (HCV) en enfermedad hepática crónica no alcohólica. Rev Méd Chile 1993; 121: 148-51.
35. VENTO S, GAROFANO T, RENZINI C, CAINELLI F, CASSALI F, GHONONZO G ET AL. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-90.
36. ARMAS MERINO R, WOLFF C, PARRAGUEZ A, SOTO JR. Excreción de porfirinas e infección por virus C de la hepatitis. Rev Méd Chile 1997; 125: 279-82.
37. ARMAS MERINO R, KRAUSE P, WOLFF C. Porfiria cutánea tarda, hepatopatía crónica por virus C y hepatocarcinoma. Caso Clínico. Rev Méd Chile 1994; 122: 72-4.
38. WOLFF C, ARMAS MERINO R, PUIG A, KRAUSE P, PARRAGUEZ A. Infección por virus C de la hepatitis en pacientes con porfiria. Rev Méd Chile 1994; 122: 294-8.
39. STOLZEL U, KÖSTLER E, KOSZKA C, STÖFFLER-MEILICKE M, SCHUPPAN D, SOMASUMDARAM R ET AL. Low prevalence of hepatitis C virus infection in Porphyria Cutanea Tarda in Germany. Hepatology 1995; 21: 1500-3.
40. MURPHY A, DOOLEY S, HILLARY IB, MURPHY GM. HCV infection in Porphyria Cutanea Tarda. Lancet 1993; 341: 1534-5.
41. NAVAS S, BOSH O, CASTILLO L, MARRIOT E, CARREÑO V. Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study. Hepatology 1995; 21: 279-84.
42. ADREONE P, CURSADO C, GRAMENZI A, GUIDETTI MS, BARDAZZI F, TOSTI A ET AL. Detection of hepatitis C virus by polymerase chain reaction and Recombinant Immunoblot assay 3.0 in porphyria cutanea tarda. Hepatology 1995; 21: 1754-5.
43. ALBERDI-JERÓNIMO E, MAGNIN BH, ENRÍQUEZ DE SALAMANCA R, BATLLE AM DEL C, STELLA AM, MELITO V ET AL. Porfiria cutánea tarda y hepatitis. Rev Arg Dermatol 1995; 76: 139-47.
44. WOLFF C, STELLA AM, ARMAS-MERINO R, PARRAGUEZ A, SILVA H, BATLLE A. Carácter adquirido de la porfiria cutánea tarda en pacientes infectados con virus C de la hepatitis. Rev Méd Chile 1998; 126: 245-50.
45. SANSONNO D, CORNACCHIULO V, IACOBELLI AR, STEFANO RD, LOSPALLUTI M, DAMMACCO F. Localization of hepatitis C virus antigen in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 1995; 21: 305-12.
46. FERRI C, MARZO E, LONGOMBARDO G, LOMBARDINI F, LA CIVITA L, VANACORE R ET AL. Interferon-alpha in mixed cryoglobulinemia patients: randomized, crossover-controlled trial. Blood 1993; 81: 1132-6.
47. MISIANI R, BELLAVITA P, FENILI D, VICARI O, MARCHESI D, SIRONI PL ET AL. Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
48. FERRI C, LA CIVITA L, ZIGNEGO AL. Extrahepatic manifestations of hepatitis C virus infection. Ann Intern Med [letter] 1996; 125: 344.
49. AGNELLO V, CHUNG RT, KAPLAN LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
50. MISIANI R, BELLAVITA P, FENILI D, BORELLI G, MARCHESI D, MASSAZZA M. Hepatitis C infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573-7.
51. JOHNSON RJ, GRETCH DR, YAMABE H, HART J, BACCHI CE, HARTWELL P ET AL. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1995; 328: 465-70.
52. GRETCH DR, JOHNSON RJ, YAMABE H, WENER MH, COREY L, ALPERS CE ET AL. Clinical, immunological, and virological features of HCV-associated membranoproliferative glomerulonephritis. En Viral Hepatitis and Liver Disease. Ed. Nishioka K, Suzuki H, Mishiro S, Oda T. Springert-Verlag, Tokyo, 1994; 218-21.
53. HOOFNAGLE JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26 (Suppl 1): 15s-20s.
54. MASON AI, LAU JYN, HOANG N, QIAN K, ALEXANDER GJM, Xu L ET AL. Association of Diabetes Mellitus and Chronic hepatitis C virus Infection. Hepatology 1999; 29:
55. ALLISON ME, WREGHITT T, PALMER CR, ALEXANDER GI. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-9.
56. ZEIN N. Hepatitis C and diabetes mellitus: An ongoing controversy. Am J Gastroenterol 1998; 93: 2320-2.
57. DICK D, JACOB S, KESLER E, STEWRD D, COOPER S, TAKIFF H ET AL. HLA association with type II diabetes and HCV infection. (Abstract). Hepatology 1996; 24: 1013A.
58. WOLFF C, MUÑOZ S, RADDATZ V. ¿Existe asociación entre virus C de la hepatitis y diabetes? Medicina (Buenos Aires) 1999; 59: 315-6.
59. MUSSINI C, GHINI M, MASCIA MT, ZANNI G, LATTUADA I, GIOVARARDI P ET AL. HCV and monoclonal gammopathies. Clin Exp Rheumatol 1995; 13 (Suppl 13): S45-9.
60. ANDREONE P, ZIGNENGO AL, CURSARO C, GRAMENZI A, GHERLINZONI F ET AL. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129: 294-8.
61. GUMBER SC, CHOPRA S. Hepatitis C. A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
62. CÁCERES M, CERDA N, RIBALTA J, WAINSTEIN E. Poliartritis como manifestación de infección por virus C de la hepatitis: Presentación de dos casos clínicos. Rev Méd Chile 1997; 125: 1357-60.
63. FERRI C, CARACCIOLO F, ZIGNEGO AL, LA CIVITA L, MONTI M, LONGOMBARDO G ET AL. Hepatitis C virus infection in patients with non-Hodgkin's Lymphoma. Br J Haematol 1994; 88: 392-4.
64. MC COLL M, CAMPBELL R. Hepatitis C virus infection in patients with lymphoproliferative disorders. Br J Haematol 1996; 92: 771-2.
65. LEVINE RA. Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129: 323-6.
66. NIEDERAU C, LANGE S, HEINTGES T, ERHARDT A, BUSCHKAMP M, HURTER D. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
67. HOOFNAGLE JH, MULLEN KD, JONES DB, RUSTGI V, DI BISCEGLIE A, PETERS M ET AL. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 3125: 1575-8.
68. LINDSAY KL. Therapy of hepatitis C: Overview. Hepatology 1997; 26 (suppl 1): 71S-77S.
69. KOFF RS. Therapy in chronic hepatitis C: say goodbye to the 6-months interferon regimen (Editorial). Am J Gastroenterol 1996; 91: 2072-4.
70. GAVIER B, MARTÍNEZ-GONZÁLEZ MA, RIEZU-BOJ JI, LASARTE JJ, GARCÍA N, CIVEIRA MP ET AL. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1647-53.
71. RODRÍGUEZ MI, SOTO JR. Estudio abierto de tratamiento de hepatitis crónica NoA-NoB con interferón. Bol Hosp S J de Dios 1997; 44: 85-91.
72. IMAI Y, KAWATA S, TAMURA S, YABUUCHI I, NODA S, INADA M ET AL. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-9.
73. DI BISCEGLIE AM, CONJEEVARAM HS, FRIED MW, SALLIE R, PARK Y, YURDAYDI C ET AL. Ribavirin as therapy for chronic hepatitis C: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
74. DUSHEIKO G, MAIN J, THOMAS H, REICHARD O, LEE C, DHILLON A ET AL. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8.
75. BODENHEIMER HC, LINDSAY KL, DAVIS GL, LEWIS JH, THUNG SN, SEEF LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-7.